Answers are grounded in this paper and cite their sources.
To the Editor: Otto Werner first described Werner syndrome (WS), an adult progeria syndrome with autosomal-recessive inheritance, in 1904. Individuals with WS have a high prevalence of vascular diseases and metabolic disorders, including nonalcoholic fatty liver disease (NAFLD).1 Herein is reported a case in which astaxanthin, a xanthophyll carotenoid, improved NAFLD in individuals with WS and diabetes mellitus. A 58-year-old woman was referred to the Department of Medicine, Division of Diabetes, Metabolism and Endocrinology, Chiba University Hospital for close examination and treatment of a skin ulcer. At age 36, she had developed bilateral cataracts; at age 55, an intractable ulcer emerged on her left leg; at age 57, she had surgery for a brain meningioma; and at age 58 she had developed diabetes mellitus. Her parents' marriage was not consanguineous. On examination, her height was 148.7 cm, weight was 42.5 kg, and body mass index was 19.2 kg/m2. Because she had progeroid facies, she underwent genetic testing and was diagnosed with WS (mutation 4/4). X-ray revealed flame-like calcifications in the Achilles tendon—a phenomenon highly characteristic of WS.2 She was prescribed a daily dose of 40 mg of telmisartan and 5 mg of atorvastatin. Initial examination results were fasting blood glucose 84 mg/dL, glycosylated hemoglobin 5.6%, immunoreactive insulin 35.1 IU/mL, total cholesterol 222 mg/dL, triglyceride 219 mg/dL, and high-density lipoprotein cholesterol 60 mg/dL. Computed tomography (CT) revealed a visceral fat area of 110.9 cm2 and severe fatty liver (Figure 1). Astaxanthin 12 mg/d was initiated, and no adverse effects were observed. CT 3 and 6 months after initiation revealed that the severity of fatty liver had gradually but significantly improved (Figure 1). The results of blood transaminase concentrations before astaxanthin initiation and 3 and 6 months after initiation were aspartate aminotransferase 40 IU/L, 41 IU/L, and 20 IU/L; alanine aminotransferase 69 IU/L, 62 IU/L, and 34 IU/L; gamma-glutamyl transferase 38 IU/L, 41 IU/L, and 35 IU/L; and cholinesterase 360 IU/L, 366 IU/L, and 331 IU/L, respectively. Liver-to-spleen Hounsfield units on CT were 0.41 before astaxanthin initiation, 0.71 at 3 months, and 0.94 at 6 months. There were no significant changes after astaxanthin initiation in hyaluronic acid, a marker of liver fibrosis; high-sensitivity C-reactive protein, a marker of inflammation; and malondialdehyde-modified low-density lipoprotein, a marker of oxidative stress. Reports suggest that 50% of individuals with WS have complicated fatty liver disease1, 3 and a high prevalence of nonalcoholic steatohepatitis (NASH).4 Although the exact etiology of NALFD and NASH has not been elucidated, the "two-hit theory" was proposed to explain the pathogenesis of these diseases. Insulin resistance seems to occur first, followed by oxidative stress. Moreover, it has been observed that individuals with WS exhibit high insulin resistance because of the accumulation of visceral fat tissue;5, 6 high oxidative stress in the fibroblasts of these individuals due to the instability of mitochondrial functions and low copper- and zinc-containing superoxide dismutase and manganese-containing superoxide dismutase activities have also been observed.7 Therefore, individuals with WS may have a genetic predisposition to NAFLD and NASH. There are a few treatment options for NAFLD and NASH, including thiazolidine and vitamin E. Astaxanthin is a strong antioxidant, which Haematococcus pluvialis, a microalgae, produces and refines; it has been reported to possess several biological functions, including stabilizing biological membranes, improving mitochondrial functions, decreasing deoxyribonucleic acid damage, and anti-inflammatory effects. In murine obesity models, it has been recently reported that astaxanthin reduces liver endoplasmic reticulum stress and activation of nuclear factor kappa B–mediated inflammation.8 It has been reported that NASH, which can be one-third of NAFLD, progresses to liver cirrhosis and hepatocellular carcinoma. Because individuals with WS have a high prevalence of malignant tumors,9 including liver tumors,10 it is essential to treat the fatty liver disease frequently found with WS. Because levels of neither oxidative stress markers nor inflammation markers, which were selected, changed after astaxanthin initiation, it is unclear how astaxanthin improved NAFLD in this woman. Nevertheless, to the best of the knowledge of the authors, this is the first report revealing that astaxanthin improves fatty liver disease in humans. Therefore, astaxanthin may become the primary treatment option for individuals with fatty liver disease, especially those with WS, although longer, large-scale, population-based, randomized controlled trials are necessary to determine the benefits of astaxanthin in the future. We thank Jiro Takahashi and Mitsunori Nishida of Fuji Chemical Co., Ltd for supplying the astaxanthin preparation. This work was supported by Health and Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare of Japan for research on measures for intractable diseases. Conflict of Interest: None of the authors have any conflict of interest. Author Contributions: Takemoto: analysis and interpretation of data, acquisition of subjects and data, preparation of manuscript. Yamaga: acquisition of subjects and data. Furuichi, Yokote: discussion, review, and editing of manuscript. Sponsor's Role: None.
No takes yet. Share an insight, caveat, or question.
Takemoto et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: